Key Takeaways A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its ...

Sanofi and Regeneron said that drug candidate Itepekimab didn’t meet primary endpoint in a phase three study, although a ...

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, ...

Sanofi (ENXTPA:SAN) announced that its AERIFY-1 trial with Regeneron Pharmaceuticals successfully met its primary endpoint, indicating progress in COPD treatment. Despite this positive news, the ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly ...